{
    "clinical_study": {
        "@rank": "146383", 
        "acronym": "ECOS UAE", 
        "arm_group": {
            "arm_group_label": "Growth Disorders"
        }, 
        "brief_summary": {
            "textblock": "This is a Middle East, Multicenter, Observational Study to evaluate Adherence and Long Term\n      Outcomes of Therapy in pediatric subjects using easypod\u2122 electromechanical device for growth\n      hormone treatment and to assess the level of adherence of subject receiving SAIZEN\u00ae via\n      easypod\u2122."
        }, 
        "brief_title": "To Assess the Level of Adherence of Subjects Receiving SAIZEN\u00ae Via Easypod\u2122 in Middle East", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Growth Disorders", 
        "condition_browse": {
            "mesh_term": "Growth Disorders"
        }, 
        "detailed_description": {
            "textblock": "Subjects will be enrolled in a multicenter longitudinal observational study.\n      Parents/subjects will provide their Informed Consent/assent to upload their data for\n      population-based analyses and, ultimately, clinical outcomes. Adherence data will be\n      primarily derived from the easypod\u2122 device combined with physician data entry of outcome\n      measures. Data will be collected both retrospectively and prospectively. This will allow the\n      establishment of adherence profiles and explore the hypothesis that patient adherence\n      support programs improve adherence and subsequent clinical outcomes. Collected data will be\n      also analyzed in a multinational pooled analysis of comparable national studies.\n\n      Primary Objective:\n\n      \u2022 To assess the level of adherence of subjects receiving SAIZEN\u00ae via easypod\u2122\n\n      Secondary Objectives:\n\n        -  To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN\u00ae\n           via easypod\u2122\n\n        -  To identify adherence subject profiling\n\n        -  To assess the impact of adherence on Insulin-like Growth Factor 1 (IGF1) (that is,\n           above, below or within normal ranges)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Administered growth hormone via the easypod\u2122 electromechanical device according to\n             Summary of Product Characteristic (SmPC)\n\n          -  Over the age of 2 years\n\n          -  Under 18 years of age, or over 18 without fusion of growth plates\n\n          -  Parent's or guardian's written informed consent, given before entering data into the\n             observational study, with the understanding that the subject or parent/guardian may\n             withdraw consent at any time without prejudice to future medical care. If the child\n             is old enough to read and write, a separate assent form will be given as defined in\n             the appropriate jurisdiction of each country\n\n        Exclusion Criteria:\n\n          -  Subjects taking growth hormone in whom growth plates have fused (that is, for taking\n             growth hormone for it's metabolic effects)\n\n          -  Contra-indications to SAIZEN\u00ae as defined in the SmPC\n\n          -  Use of an investigational drug or participation in another interventional clinical\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric subjects (aged 2-18) who are taking SAIZEN\u00ae for registered indications using the\n        easypod\u2122 electromechanical device."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015286", 
            "org_study_id": "EMR 200104-534"
        }, 
        "intervention": {
            "arm_group_label": "Growth Disorders", 
            "description": "Saizen\u00ae (Somatropin) as per Summary of Product Characteristics administered by easypod\u2122", 
            "intervention_name": "easypod\u2122", 
            "intervention_type": "Device", 
            "other_name": "Somatropin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Growth disorders", 
            "Saizen", 
            "Easypod", 
            "Growth hormone", 
            "Pediatric subject"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "last_name": "Merck KGaA Communication Center", 
                "phone": "+49-6151-72-5200"
            }, 
            "facility": {
                "address": {
                    "city": "please contact the Merck KGaA Communication Center located in", 
                    "country": "Germany", 
                    "state": "Darmstadt"
                }, 
                "name": "For Recruiting Locations in the United Arab Emirates and the Kingdom of Saudi Arabia"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Easypod Connect: A Regional, Multicentre, Observational Study to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using \"Easypod\u2122\" Electromechanical Device for Growth Hormone Treatment", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49-6151-72-5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Serono Middle East FZ LLC", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Arab Emirates: General Authority for Health Services for Abu Dhabi", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean percent of daily recorded adherence", 
            "safety_issue": "No", 
            "time_frame": "At least 6 months and up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Correlation of adherence and growth outcome (change in: height velocity [HV], height velocity-standard deviation score [HV-SDS], height, height-standard deviation score[height SDS]) after each year of SAIZEN\u00ae treatment with easypod\u2122", 
                "measure": "Correlation of adherence and growth outcome after each year of SAIZEN\u00ae treatment with easypod\u2122", 
                "safety_issue": "No", 
                "time_frame": "At least 6 months and up to 5 years"
            }, 
            {
                "measure": "Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment", 
                "safety_issue": "Yes", 
                "time_frame": "At least 6 months and up to 5 years"
            }, 
            {
                "measure": "Correlation of adherence with current IGF-1 status (that is, above, below or within normal ranges)", 
                "safety_issue": "Yes", 
                "time_frame": "At least 6 months and up to 5 years"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Serono Middle East FZ LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}